98%
921
2 minutes
20
Aims: Intestinal ischemia-reperfusion (II/R) injury predominantly causes acute lung injury (ALI), and in severe instances, acute respiratory distress syndrome, both associated with high mortality. Electroacupuncture (EA) excels in regulating autonomic nervous system balance and safeguarding organ function. This study delved into EA's impacts and mechanisms on II/R-induced ALI.
Methods And Results: A rat II/R model was created by occluding the superior mesenteric artery for 1 h followed by reperfusion, with EA stimulation applied 30 min before reperfusion. Vagotomy and chemical sympathectomy explored EA's link with the autonomic nervous system. Findings revealed EA mitigated II/R-induced intestinal and lung pathological damage and edema, increased Claudin-5 and ZO-1 expression, inhibited local and systemic inflammation. Additionally, EA reduced the total protein concentration in bronchoalveolar lavage fluid while increasing the levels of pulmonary surfactant related proteins SP-A and SP-D, and decreased the low/high frequency ratio of heart rate variability. EA enhanced central parasympathetic activity, peripheral acetylcholine, vasoactive intestinal peptide in mesenteric lymph nodes, and lung α7nAChR expression, while reducing hypothalamic-pituitary-adrenal axis substances and peripheral blood glutamic acid/γ-aminobutyric acid ratio. However, the protective effect of EA disappeared after vagotomy in rats and partially weakened after sympathetic nerve chemical resection.
Conclusion: EA alleviates II/R-ALI via the vagus-sympathetic nerve pathway, highlighting its therapeutic potential.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.intimp.2025.115484 | DOI Listing |
Eur J Pharmacol
September 2025
Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China; Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou, P. R. China. Electronic address:
Drug-induced liver injury is a major cause of acute liver failure. Crizotinib is a first-line treatment for patients with cellular-mesenchymal epithelial transition factor (c-MET), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer. Although some patients treated with crizotinib experience hepatic adverse effects, the underlying mechanisms remain unclear.
View Article and Find Full Text PDFHeart Lung
September 2025
Department of Cardiology, School of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. Electronic address:
Background: Acute heart failure with reduced ejection fraction (AHF) remains a leading cause of ED visits, hospitalizations, and in-hospital mortality.
Objectives: To evaluate the prognostic utility of the Scottish Inflammatory Prognostic Score (SIPS) in patients with AHF.
Methods: This retrospective study analyzed 508 patients admitted with AHF between November 2022 and November 2024.
Int Immunopharmacol
September 2025
Key Laboratory of Anesthesia and Intensive Care Research, Harbin, China; Department of Anesthesiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address:
Aims: Intestinal ischemia-reperfusion (II/R) injury predominantly causes acute lung injury (ALI), and in severe instances, acute respiratory distress syndrome, both associated with high mortality. Electroacupuncture (EA) excels in regulating autonomic nervous system balance and safeguarding organ function. This study delved into EA's impacts and mechanisms on II/R-induced ALI.
View Article and Find Full Text PDFCrit Care Explor
September 2025
Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
Objective: To identify distinct phenotypes of acute respiratory distress syndrome (ARDS) developing after hematopoietic cell transplantation (HCT), using routinely available clinical data at ICU admission.
Design: Multicenter retrospective cohort study using latent class analysis.
Setting: ICUs across three Mayo Clinic campuses (Minnesota, Florida, and Arizona).
Sci Bull (Beijing)
August 2025
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430072, China; State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Ganzhou 341000, China; Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou 341000